Towards a better understanding of cohesin mutations in AML

Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators of cell proliferation, differentiation, and survival. The selective advantage of increased proliferation, improved survival, and reduced differentiation on leukemia progression is immediately obvious. Recent large...

Full description

Bibliographic Details
Authors: Cuartero, Sergi; Innes, Andrew J.; Merkenschlager, Matthias
Format: Article
Status:Published version
Publication date:2019
Country:España
Institution:Universitat Pompeu Fabra
Repository:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/44013
Online Access:http://hdl.handle.net/10230/44013
http://dx.doi.org/10.3389/fonc.2019.00867
Access Level:Open access
Keyword:AML
Cohesin
Hematopoiesis
Inflammation
Interferon
Leukemia
_version_ 1878741103575826432
author Cuartero, Sergi
author2 Innes, Andrew J.
Merkenschlager, Matthias
author2_role author
author
author_browse Cuartero, Sergi
Innes, Andrew J.
Merkenschlager, Matthias
author_facet Cuartero, Sergi
Innes, Andrew J.
Merkenschlager, Matthias
author_role author
collection Repositorio Digital de la UPF
description Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators of cell proliferation, differentiation, and survival. The selective advantage of increased proliferation, improved survival, and reduced differentiation on leukemia progression is immediately obvious. Recent large-scale sequencing efforts have uncovered numerous novel AML-associated mutations. Interestingly, a substantial fraction of the most frequently mutated genes encode general regulators of transcription and chromatin state. Understanding the selective advantage conferred by these mutations remains a major challenge. A striking example are mutations in genes of the cohesin complex, a major regulator of three-dimensional genome organization. Several landmark studies have shown that cohesin mutations perturb the balance between self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. Among these mechanisms is a role for cohesin in the control of inflammatory responses in HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive HSPC differentiation. Consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for AML progression. In this review, we discuss recent progress in understanding cohesin mutations in AML, and speculate whether vulnerabilities associated with these mutations could be exploited therapeutically.
eu_rights_str_mv openAccess
format article
id ES_df2522f2edceeeecf8640bbf01ebb92a
institution Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
network_acronym_str ES
network_name_str España
oai_identifier_str oai:repositori.upf.edu:10230/44013
publishDate 2019
publishDateSort 2019
publisher Frontiers
publisherStr Frontiers
reponame_str Repositorio Digital de la UPF
spelling Towards a better understanding of cohesin mutations in AML Cuartero, Sergi Innes, Andrew J. Merkenschlager, Matthias AML Cohesin Hematopoiesis Inflammation Interferon Leukemia Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators of cell proliferation, differentiation, and survival. The selective advantage of increased proliferation, improved survival, and reduced differentiation on leukemia progression is immediately obvious. Recent large-scale sequencing efforts have uncovered numerous novel AML-associated mutations. Interestingly, a substantial fraction of the most frequently mutated genes encode general regulators of transcription and chromatin state. Understanding the selective advantage conferred by these mutations remains a major challenge. A striking example are mutations in genes of the cohesin complex, a major regulator of three-dimensional genome organization. Several landmark studies have shown that cohesin mutations perturb the balance between self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. Among these mechanisms is a role for cohesin in the control of inflammatory responses in HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive HSPC differentiation. Consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for AML progression. In this review, we discuss recent progress in understanding cohesin mutations in AML, and speculate whether vulnerabilities associated with these mutations could be exploited therapeutically. Frontiers http://hdl.handle.net/10230/44013 http://dx.doi.org/10.3389/fonc.2019.00867
spellingShingle Towards a better understanding of cohesin mutations in AML
Cuartero, Sergi
AML
Cohesin
Hematopoiesis
Inflammation
Interferon
Leukemia
status_str publishedVersion
title Towards a better understanding of cohesin mutations in AML
title_full Towards a better understanding of cohesin mutations in AML
title_fullStr Towards a better understanding of cohesin mutations in AML
title_full_unstemmed Towards a better understanding of cohesin mutations in AML
title_short Towards a better understanding of cohesin mutations in AML
title_sort Towards a better understanding of cohesin mutations in AML
topic AML
Cohesin
Hematopoiesis
Inflammation
Interferon
Leukemia
topic_facet AML
Cohesin
Hematopoiesis
Inflammation
Interferon
Leukemia
url http://hdl.handle.net/10230/44013
http://dx.doi.org/10.3389/fonc.2019.00867